Pharmaceutical companies are appealing a High Court judgement that upheld the National Institute for Health and Clinical Excellence's decision to restrict the use of anti-dementia medicines for NHS patients in the early stages of Alzheimer's disease.

Eisai and Pfizer, which are launching the appeal, say it is based on the need for greater transparency from NICE about the cost-effectiveness model used for these treatments.